These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 25649051

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
    Rocha JF, Sicard É, Fauchoux N, Falcão A, Santos A, Loureiro AI, Pinto R, Bonifácio MJ, Nunes T, Almeida L, Soares-da-Silva P.
    Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
    Svetel M, Tomić A, Kresojević N, Kostić V.
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
    [Abstract] [Full Text] [Related]

  • 7. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.
    Clin Neuropharmacol; 2008 Mar; 31(1):2-18. PubMed ID: 18303486
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
    Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W.
    Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF, Santos A, Falcão A, Lopes N, Nunes T, Pinto R, Soares-da-Silva P.
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR, Odin P, Ferreira JJ, Antonini A, Rascol O, Kurtis MM, Storch A, Bannister K, Soares-da-Silva P, Costa R, Magalhães D, Rocha JF.
    BMC Neurol; 2022 Mar 12; 22(1):88. PubMed ID: 35279112
    [Abstract] [Full Text] [Related]

  • 18. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    Neurology; 1998 May 12; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.